Exchange: NYSE·Updated 02:56 AM EDT
News
all
press releases
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
Zacks
More News
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference PR Newswire INDIANAPOLIS, Sept. 1, 2026 INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in...
PR Newswire
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Zacks
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
Stocktwits
Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Key PointsIt has agreed to pay up to nearly $2.88 billion for a clinical-stage biotech...
Nasdaq News: Markets
Eli Lilly CEO on branching out beyond obesity drugs
Eli Lilly CEO on branching out beyond obesity drugs...
CNBC Television-YouTube
Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’
In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in technologies to transform the treatment of other diseases.
Stocktwits
Stocks making the biggest moves midday: PG&E, Edison International, Apple, Howmet Aerospace, Eli Lilly & more
These are some of the stocks posting the largest moves midday...
CNBC: Top News
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
Zacks
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
Zacks

Advertisement|Remove ads.